Enable JavaScript to visit this website.

ASPIRE Canada Home - English

PFIZER IS PLEASED TO ANNOUNCE THE 2018 ASPIRE BREAST CANCER RESEARCH AWARDS PROGRAM FOR CANADA. A COMPETITIVE, PEER-REVIEWED GRANTS PROGRAM INITIATED AND SPONSORED BY PFIZER FOR INVESTIGATORS IN CANADA

As competition for research funding increases, the ASPIRE Breast Cancer Research Program underscores Pfizer’s commitment to supporting investigators in advancing their academic research in breast cancer.

Mission

The mission of the ASPIRE Awards is to support clinical research in breast cancer through a competitive grants program to advance knowledge in the treatment and disease management of the disease.
 

Background

This program aims to support continuous medical research to maximize available therapies by improving medical knowledge and clinical management of breast cancer.

Request for Proposals

Pfizer invites investigators to apply for the 2018 ASPIRE Breast Cancer Research Awards Program through submission of innovative clinical research proposals designed to accomplish the mission of advancing knowledge in the treatment and management of breast cancer.

Eligible Areas of Research

Clinical & Translational Research


  • Innovative clinically-oriented or translational projects with potential for meaningful clinical impact in breast cancer patient management           and care
  • New projects evaluating novel therapies, including but not exclusive to CDK4/6 inhibitors

    And

    • The “TOP 10” research priorities in breast cancer based on feedback from more than a 1000 patients, families, caregivers and                  health care providers

    Available Awards

    There will be 2 categories of Awards


    • Established investigator Award
    • Early investigator Award (within 5 years of residency completion if MD, or 5 years of 1st faculty position for non-MD)

    Budget and potential funding


    • Maximum budget $200,000 per project (which is including 30% max overhead)
    • At least, 2 projects will be funded according to ranking determined by the external review panel.

    Studies conflicting with Pfizer-sponsored clinical and scientific development programs are not eligible. Therefore, a preliminary review of submissions will be completed by Pfizer in order to ensure proposals are within the scope of research areas and that there are no concerns with the proposed work from an intellectual property perspective.

    (Please contact Florence Dequen at
    [email protected] for any question related to Pfizer development program).

     

    Questions

    See the Frequently Asked Questions (FAQ) for help.

    You may also e-mail questions to [email protected]